Bone marrow mesenchymal stromal cells from patients with acute and chronic graft-versus-host disease deploy normal phenotype, differentiation plasticity, and immune-suppressive activity

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 5, 2015, Pages 934-940

  Copland, Ian B ^a   Qayed, Muna ^a,b   Garcia, Marco A ^c   Galipeau, Jacques ^a,b   Waller, Edmund K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autologous; GVHD; Immunosuppression; MSC; Tolerance

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPHENOTYPING; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MESENCHYMAL STROMA CELL; MESODERMAL CELL; MIDDLE AGED; PRESCHOOL CHILD; PROTEIN EXPRESSION; SCHOOL CHILD; STEM CELL EXPANSION; T LYMPHOCYTE; TANDEM REPEAT; UPREGULATION; ACUTE DISEASE; ALLOGRAFT; BONE MARROW CELL; CELL CULTURE; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; PATHOLOGY;

ACUTE DISEASE; ADOLESCENT; ADULT; ALLOGRAFTS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE TOLERANCE; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED;

EID: 84928124689     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.01.014     Document Type: Article

References (52)

1. Cragg L., Blazar B.R., Defor T., et al. Arandomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000, 6:441-447.
2. Cutler C., Antin J.H. Novel drugs for the prevention and treatment of acute GVHD. Curr Pharm Des 2008, 14:1962-1973.
3. Lee S.J., Zahrieh D., Agura E., et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004, 104:1559-1564.
4. Macmillan M.L., Couriel D., Weisdorf D.J., et al. Aphase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 2007, 109:2657-2662.
5. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
6. Weisdorf D.J. Chronic graft-versus-host disease: where is promise for the future?. Leukemia 2005, 19:1532-1535.
7. Stagg J., Galipeau J. Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr Mol Med 2013, 13:856-867.
8. Introna M., Lucchini G., Dander E., et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant 2014, 20:375-381.
9. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
10. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
11. Lucchini G., Introna M., Dander E., et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant 2010, 16:1293-1301.
12. Ringden O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
13. von Bonin M., Stolzel F., Goedecke A., et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009, 43:245-251.
14. Galipeau J. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?. Cytotherapy 2013, 15:2-8.
15. Eliopoulos N., Stagg J., Lejeune L., et al. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 2005, 106:4057-4065.
16. Isakova I.A., Lanclos C., Bruhn J., et al. Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment invivo. PLoS One 2014, 9:e87238.
17. Nauta A.J., Westerhuis G., Kruisselbrink A.B., et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006, 108:2114-2120.
18. Lazarus H.M., Haynesworth S.E., Gerson S.L., et al. Exvivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995, 16:557-564.
19. Dimitriou H., Linardakis E., Martimianaki G., et al. Properties and potential of bone marrow mesenchymal stromal cells from children with hematologic diseases. Cytotherapy 2008, 10:125-133.
20. Zhao Z.G., Liang Y., Li K., et al. Phenotypic and functional comparison of mesenchymal stem cells derived from the bone marrow of normal adults and patients with hematologic malignant diseases. Stem Cells Dev 2007, 16:637-648.
21. Andre T., Meuleman N., Stamatopoulos B., et al. Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells. PLoS One 2013, 8:e59756.
22. Copland I.B., Garcia M.A., Waller E.K., et al. The effect of platelet lysate fibrinogen on the functionality of MSCs in immunotherapy. Biomaterials 2013, 34:7840-7850.
23. Romieu-Mourez R., Francois M., Boivin M.N., et al. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. JImmunol 2007, 179:1549-1558.
24. Romieu-Mourez R., Francois M., Boivin M.N., et al. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. JImmunol 2009, 182:7963-7973.
25. Butler J.M., Schoske R., Vallone P.M., et al. Allele frequencies for 15 autosomal STR loci on U.S. Caucasian, African American, and Hispanic populations. JForensic Sci 2003, 48:908-911.
26. Bartsch K., Al-Ali H., Reinhardt A., et al. Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used. Transplantation 2009, 87:217-221.
27. Rieger K., Marinets O., Fietz T., et al. Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. Exp Hematol 2005, 33:605-611.
28. Wang J., Liu K., Lu D.P. Mesenchymal stem cells in stem cell transplant recipients are damaged and remain of host origin. Int J Hematol 2005, 82:152-158.
29. Pozzi S., Lisini D., Podesta M., et al. Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation. Exp Hematol 2006, 34:934-942.
30. Villaron E.M., Almeida J., Lopez-Holgado N., et al. Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation. Haematologica 2004, 89:1421-1427.
31. Krampera M., Galipeau J., Shi Y., et al. Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 2013, 15:1054-1061.
32. Andre T., Najar M., Stamatopoulos B., et al. Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells. Cancer Immunol Immunother 2015, 64:213-224.
33. Fried W., Chamberlin W., Kedo A., et al. Effects of radiation on hematopoietic stroma. Exp Hematol 1976, 4:310-314.
34. Galotto M., Berisso G., Delfino L., et al. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol 1999, 27:1460-1466.
35. Corazza F., Hermans C., Ferster A., et al. Bone marrow stroma damage induced by chemotherapy for acute lymphoblastic leukemia in children. Pediatr Res 2004, 55:152-158.
36. Li J., Law H.K., Lau Y.L., Chan G.C. Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. Br J Haematol 2004, 127:326-334.
37. Bieback K., Hecker A., Kocaomer A., et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009, 27:2331-2341.
38. Griffiths S., Baraniak P.R., Copland I.B., et al. Human platelet lysate stimulates high-passage and senescent human multipotent mesenchymal stromal cell growth and rejuvenation invitro. Cytotherapy 2013, 15:1469-1483.
39. Kemp K., Morse R., Sanders K., et al. Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells. Ann Hematol 2011, 90:777-789.
40. Cao J., Tan M.H., Yang P., et al. Effects of adjuvant chemotherapy on bone marrow mesenchymal stem cells of colorectal cancer patients. Cancer Lett 2008, 263:197-203.
41. Schwartz G.N., Warren M.K., Rothwell S.W., et al. Post-chemotherapy and cytokine pretreated marrow stromal cell layers suppress hematopoiesis from normal donor CD34+ cells. Bone Marrow Transplant 1998, 22:457-468.
42. Carlo-Stella C., Tabilio A., Regazzi E., et al. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors. Bone Marrow Transplant 1997, 20:465-471.
43. Arnulf B., Lecourt S., Soulier J., et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007, 21:158-163.
44. Li B., Fu J., Chen P., Zhuang W. Impairment in immunomodulatory function of mesenchymal stem cells from multiple myeloma patients. Arch Med Res 2010, 41:623-633.
45. Francois M., Romieu-Mourez R., Li M., Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 2012, 20:187-195.
46. Wobus M., Benath G., Ferrer R.A., et al. Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. Exp Hematol 2012, 40:867-876.
47. Melief S.M., Schrama E., Brugman M.H., et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 2013, 31:1980-1991.
48. Jitschin R., Mougiakakos D., Von Bahr L., et al. Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation. Stem Cells 2013, 31:1715-1725.
49. Hoogduijn M.J., Popp F.C., Grohnert A., et al. Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation 2010, 90:124-126.
50. Kheradmand T., Wang S., Bryant J., et al. Ethylenecarbodiimide-fixed donor splenocyte infusions differentially target direct and indirect pathways of allorecognition for induction of transplant tolerance. JImmunol 2012, 189:804-812.
51. Turley D.M., Miller S.D. Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimentalautoimmune encephalomyelitis. JImmunol 2007, 178:2212-2220.
52. Florek M., Sega E.I., Leveson-Gower D.B., et al. Single dose of autologous apoptotic cells preceding transplantation significantly enhances survival in lethal murine graft versus host models. Blood 2014, 124(11):1832-1842.